Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Multiple Myeloma × Immunoconjugates × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 4 Recurrence 3 Rectal Neoplasms 2 Neoplasms 2 Neoplasm Metastasis 2 Colorectal Neoplasms 2 Stomach Neoplasms 1 Prostatic Neoplasms 1 Multiple Myeloma 1 Lymphoma, T-Cell, Peripheral 1 Lymphoma, B-Cell 1 Lymphoma 1 Colonic Neoplasms 1 Burkitt Lymphoma 1 Brain Neoplasms 1 Alopecia 1

Interventions

Dexamethasone 672 Bortezomib 378 Lenalidomide 361 Cyclophosphamide 288 Melphalan 218 Calcium Dobesilate 196 daratumumab 184 pomalidomide 161 carfilzomib 145 Thalidomide 103 fludarabine 100 fludarabine phosphate 96 Peripheral Blood Stem Cell Transplantation 95 Filgrastim 95 ixazomib 74 Granulocyte Colony-Stimulating Factor 69 Whole-Body Irradiation 68 dexamethasone acetate 66 Mycophenolic Acid 65 Busulfan 65 Tacrolimus 58 dexamethasone 21-phosphate 56 Prednisone 55 Cyclosporine 53 auricularum 52 isatuximab 51 elotuzumab 50 belantamab mafodotin 49 Antilymphocyte Serum 46 Etoposide 44

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03489525 2022-03-28

MEDI2228

MedImmune LLC

Phase 1 Completed

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡